Saturday 17 October 2026
Export MDXG’s income statement to Excel — free account
MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
4.43
0.25
−5.34%
Follow MDXG
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 7 | 2 | 4 | 3 | 2 | 5 | 5 | 4 |
P/E ratio |
20.52 | 34.36 | 19.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.28 | 3,650.00 |
Altman Z-Score |
9.38 | 14.22 | 8.03 | 1.34 | 2.77 | 2.96 | 4.58 | 3.52 | 20.32 | 10.79 |
P/S ratio |
2.39 | 4.05 | 2.85 | 1.25 | 2.75 | 3.96 | 2.71 | 0.53 | 4.29 | 4.19 |
Altman Z″-Score (non-manufacturers) |
8.06 | 6.87 | 4.02 | (0.86) | 0.65 | (0.66) | (0.38) | (1.40) | 3.10 | 4.48 |
P/FCF ratio |
13.71 | 21.92 | 36.99 | 0.00 | 0.00 | 0.00 | 0.00 | 7.33 | 23.94 | 55.23 |
Beneish M-Score |
(2.68) | (2.83) | (1.09) | (2.46) | (2.77) | (2.43) | 75.28 | (5.60) | (2.75) | (2.88) |
P/Operating CF |
40.09 | 75.28 | 89.39 | (59.63) | (206.23) | (95.74) | (35.06) | 123.22 | 66.02 | 63.12 |
P/B ratio |
3.90 | 7.32 | 6.42 | 0.00 | 8,128.44 | 0.00 | 23.57 | 3.81 | 18.67 | 6.98 |
Price to Tangible BV |
4.49 | 8.73 | 7.77 | 0.00 | 0.00 | 0.00 | 121.99 | 9.42 | 31.46 | 10.36 |
EV/Sales |
2.04 | 3.81 | 2.75 | 1.19 | 2.60 | 3.77 | 2.70 | 0.40 | 4.20 | 4.03 |
EV/EBITDA |
10.82 | 20.47 | 21.80 | 0.00 | 0.00 | 0.00 | 0.00 | 48.96 | 25.79 | 111.83 |
EV/Operating CF |
11.52 | 20.07 | 33.01 | (17.85) | (317.27) | (30.93) | (20.48) | 4.02 | 21.45 | 37.47 |
EV/FCF |
11.68 | 20.59 | 35.66 | (16.46) | (115.34) | (26.88) | (19.39) | 5.58 | 23.46 | 53.18 |
Quick Ratio |
3.76 | 3.51 | 2.95 | 2.50 | 3.03 | 2.39 | 1.51 | 0.64 | 0.61 | 2.00 |
Current Ratio |
4.32 | 4.21 | 3.57 | 3.08 | 3.51 | 2.71 | 1.83 | 1.04 | 1.06 | 2.49 |
Net Debt/EBITDA |
(1.88) | (1.32) | (0.81) | 1.49 | 46.38 | 1.29 | 0.28 | (15.27) | (0.52) | (4.30) |
Debt/Assets |
5.24% | 7.13% | 20.54% | 29.19% | 26.27% | 24.19% | 39.28% | 0.19% | 0.24% | 0.02% |
Debt/Equity |
0.07 | 0.10 | 0.34 | (2.78) | 602.13 | (325.82) | 1.91 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.38 | 1.39 | 1.57 | 1.49 | 1.24 | 1.34 | 2.06 | 2.94 | 2.04 | 1.35 |
Operating CF/Net income |
1.52 | 1.56 | 0.46 | 0.49 | 0.12 | 0.36 | 1.54 | (1.19) | 0.97 | 61.15 |
Capex/Depreciation |
(0.07) | (0.28) | (0.58) | (0.37) | (0.56) | (0.50) | (0.25) | (1.46) | (0.88) | (0.99) |
Interest Coverage |
— | 58.51 | 5.75 | (2.94) | (1.42) | (5.72) | (4.49) | (7.45) | — | — |
| 21.61% | 25.26% | 93.37% | 410.78% | 48,297.06% | (486.62%) | (60.87%) | (48.57%) | 62.60% | 0.32% | |
| 16.02% | 16.87% | 28.37% | (20.47%) | (8.42%) | (45.14%) | (17.64%) | (24.56%) | 41.16% | 0.24% | |
ROIC |
36.84% | 34.22% | 21.12% | 0.00% | 0.00% | 0.00% | (42.68%) | (51.46%) | 61.99% | 0.56% |
Return on Tangible Assets |
22.29% | 27.86% | 46.50% | (37.34%) | (14.24%) | (73.81%) | (37.48%) | (150.45%) | 380.12% | 0.44% |
Average Days of Receivables |
66.01 | 58.41 | 61.16 | 58.71 | 61.98 | 66.86 | 39.45 | 0.46 | 0.75 | 110.55 |
Research and Development Expense of Revenue |
3.61% | 3.54% | 3.94% | 4.74% | 4.10% | 4.72% | 3.72% | 4.39% | 5.57% | 6.47% |
Selling, General and Administrative Expense of Revenue |
63.59% | 64.52% | 65.67% | 77.91% | 80.51% | 72.92% | 66.23% | 71.99% | 68.54% | 78.21% |
Intangible Assets out of Total Assets |
0.10 | 0.12 | 0.10 | 0.15 | 0.13 | 0.13 | 0.17 | 0.24 | 0.25 | 0.22 |
Share Based Compensation of Revenue |
3.92% | 4.85% | 5.28% | 4.23% | 5.85% | 6.19% | 4.03% | 4.11% | 6.60% | 8.00% |
Graham Net Nets |
0.19 | 0.09 | 0.07 | (0.16) | (0.06) | (0.04) | (0.01) | 0.00 | 0.00 | 0.07 |
Graham Number |
3.59 | 2.88 | 3.32 | 1.09 | 0.00 | 0.15 | 0.00 | 0.00 | 3.09 | 0.26 |
Earnings Yield |
4.87% | 2.91% | 5.08% | (11.11%) | (2.48%) | (8.48%) | (3.16%) | (15.67%) | 4.70% | 0.03% |
Free Cash Flow Yield |
7.29% | 4.56% | 2.70% | (5.79%) | (0.82%) | (3.54%) | (5.14%) | 13.65% | 4.18% | 1.81% |
Revenue per Share |
2.83 | 2.37 | 2.76 | 2.37 | 2.19 | 2.29 | 2.80 | 3.40 | 3.03 | 2.09 |
Operating CF per Share |
0.50 | 0.45 | 0.23 | (0.16) | (0.02) | (0.28) | (0.37) | 0.34 | 0.59 | 0.23 |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.01) | (0.03) | (0.04) | (0.02) | (0.09) | (0.05) | (0.07) |
Free Cash Flow per Share |
0.49 | 0.44 | 0.21 | (0.17) | (0.05) | (0.32) | (0.39) | 0.24 | 0.54 | 0.16 |
Cash per Share |
1.12 | 0.71 | 0.70 | 0.58 | 0.79 | 0.89 | 0.65 | 0.43 | 0.26 | 0.32 |
Shareholders Equity per Share |
1.74 | 1.31 | 1.23 | (0.16) | 0.00 | 0.00 | 0.32 | 0.47 | 0.70 | 1.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.74 | 1.31 | 1.23 | (0.16) | 0.00 | 0.00 | 0.32 | 0.47 | 0.70 | 1.26 |
Free Cash Flow |
72.97 | 64.52 | 24.79 | (19.41) | (5.45) | (34.82) | (41.63) | 25.80 | 57.54 | 16.80 |
Working Capital |
213.21 | 146.29 | 118.25 | 90.64 | 106.17 | 101.46 | 55.92 | 2.50 | 2.94 | 75.81 |
Capital Expenditures |
(1.03) | (1.68) | (1.99) | (1.51) | (3.47) | (4.55) | (2.22) | (10.00) | (5.40) | (7.05) |
Net Current Asset Value |
191.37 | 121.08 | 67.93 | (55.22) | (39.32) | (41.56) | (9.52) | 0.86 | 1.29 | 66.28 |
EV/EBIT |
13.34 | 22.57 | 23.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.21 | 1,010.79 |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.03 | 0.02 | 0.03 |
Price to Operating Income |
15.66 | 24.02 | 24.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.80 | 1,049.70 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.16 | 1.02 | 0.49 | 0.52 | 0.68 | 0.80 | 0.73 | 0.39 | 0.44 | 0.52 |
Cash ROIC |
16.56% | 20.39% | 9.05% | (19.80%) | (3.99%) | (24.09%) | (24.62%) | 27.16% | 56.66% | 10.04% |
Accounts Receivable Turnover |
6.37 | 6.36 | 6.63 | 6.36 | 5.59 | 6.38 | 18.25 | 647.05 | 9.47 | 3.67 |
Accounts Payable Turnover |
6.66 | 7.30 | 6.24 | 6.10 | 4.91 | 4.50 | 3.66 | 3.12 | 3.54 | 3.42 |
Inventory Turnover |
2.97 | 2.68 | 3.19 | 3.93 | 3.64 | 4.04 | 3.43 | 2.86 | 2.58 | 2.45 |
Average Days of Payables |
72.63 | 45.02 | 60.45 | 63.87 | 68.02 | 81.34 | 73.79 | 149.11 | 87.61 | 134.92 |
Days of Inventory on Hand |
126.68 | 144.65 | 140.44 | 99.59 | 104.90 | 96.15 | 77.13 | 160.36 | 98.11 | 210.17 |
Average Receivables |
65.77 | 54.85 | 48.48 | 42.09 | 43.28 | 38.91 | 16.40 | 0.56 | 33.90 | 60.45 |
Average Payables |
10.97 | 8.23 | 8.75 | 7.92 | 8.08 | 8.74 | 11.79 | 11.66 | 9.95 | 9.03 |
Average Inventory |
24.57 | 22.41 | 17.10 | 12.29 | 10.88 | 9.73 | 12.55 | 12.73 | 13.64 | 12.64 |
Average Assets |
303.28 | 251.48 | 205.24 | 179.68 | 194.98 | 184.60 | 145.01 | 122.05 | 157.26 | 164.59 |
Average Common Equity |
224.83 | 167.91 | 62.36 | (8.95) | (0.03) | 17.12 | 42.03 | 61.73 | 103.40 | 120.49 |
Columns are period end dates